| Bioactivity | ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2]. |
| Invitro | ABP 215 (Bevacizumab-awwb) 与 VEGF-A 结合，阻止 VEGF-A 与内皮细胞表面的 VEGF 受体结合，抑制内皮细胞增殖和新血管形成，从而导致肿瘤脉管系统正常化。 |
| Name | ABP 215 |
| CAS | 1438851-35-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10(4):678-691. [2]. Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17(36):5119-5127. |